Literature DB >> 21544672

Regulatory T cells but not T helper 17 cells are modulated in an animal model of Graves' hyperthyroidism.

Jin Zhou1, Mei Bi, Chenling Fan, Xizhu Song, Rong Yang, Shujie Zhao, Li Li, Yushu Li, Weiping Teng, Zhongyan Shan.   

Abstract

Graves' disease (GD) involves auto-immunity against thyroid cell antigens, but the reasons for the induction of auto-immunity are uncertain. We wished to investigate the role of T helper 17 (Th17) and regulatory T cells (Treg) in a mouse model of Graves' hyperthyroidism. The model was generated by immunizing mice with adenovirus expressing the autoantigen thyroid-stimulating hormone receptor (Ad-TSHR289). The frequencies of splenic Th17 and Treg were determined by flow cytometry. The levels of interleukin-17(IL-17), forkhead box P3 (Foxp3), and orphan retinoic acid nuclear receptor (RORγt) mRNA were determined by real-time PCR. The number of CD4(+)CD25(+)Foxp3(+) T lymphocyte was significantly reduced in the Ad-TSHR289 group compared with the Ad-control (P < 0.05). mRNA level for Foxp3 was less abundant in Ad-TSHR289 group compared with Ad-control (P < 0.05). However, CD4(+)IL-17(+) T-cell subpopulation and expression of RORγt mRNA did not differ significantly between Ad-TSHR289 and Ad-control groups (P > 0.05). Nevertheless, in Ad-TSHR289 group, a profound increase in the Th17/Treg ratios was found. The present study demonstrates that Th17 is not involved in promoting Graves' hyperthyroidism, while Treg and the ratio of Th17/Treg might play a role in the pathogenesis of Graves' hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544672     DOI: 10.1007/s10238-011-0137-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  27 in total

Review 1.  IL-2, regulatory T cells, and tolerance.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

Review 2.  The thyroid and autoimmunity.

Authors:  Corina Lichiardopol; Maria Moţa
Journal:  Rom J Intern Med       Date:  2009

3.  Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ.

Authors:  Mehdi Anvari; Omid Khalilzadeh; Alireza Esteghamati; Fatemeh Momen-Heravi; Mahdi Mahmoudi; Shadi Abdar Esfahani; Armin Rashidi; Aliakbar Amirzargar
Journal:  Endocrine       Date:  2010-03-05       Impact factor: 3.633

Review 4.  Natural regulatory T cells and self-tolerance.

Authors:  Ronald H Schwartz
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

Review 5.  Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.

Authors:  Lawrence Steinman
Journal:  Nat Rev Drug Discov       Date:  2005-06       Impact factor: 84.694

Review 6.  Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective.

Authors:  Casey T Weaver; Robin D Hatton
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

Review 7.  Insight into Graves' hyperthyroidism from animal models.

Authors:  Sandra M McLachlan; Yuji Nagayama; Basil Rapoport
Journal:  Endocr Rev       Date:  2005-04-12       Impact factor: 19.871

8.  Low-dose immunization with adenovirus expressing the thyroid-stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease.

Authors:  Chun-Rong Chen; Pavel Pichurin; Gregorio D Chazenbalk; Holly Aliesky; Yuji Nagayama; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2003-10-23       Impact factor: 4.736

9.  The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

Authors:  Chun-Rong Chen; Pavel Pichurin; Yuji Nagayama; Francesco Latrofa; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

10.  Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population.

Authors:  Yoshiyuki Ban; Teruaki Tozaki; Matsuo Taniyama; Yasuko Nakano; Kei-Ichiro Yoneyama; Yoshio Ban; Tsutomu Hirano
Journal:  Autoimmunity       Date:  2009-02       Impact factor: 2.815

View more
  5 in total

1.  Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model.

Authors:  Q Yuan; Y Zhao; X Zhu; X Liu
Journal:  J Endocrinol Invest       Date:  2016-11-07       Impact factor: 4.256

2.  Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.

Authors:  Sarah Côté-Bigras; Viet Tran; Sylvie Turcotte; Marek Rola-Pleszczynski; Jean Verreault; Diane Rottembourg
Journal:  Endocrine       Date:  2015-12-23       Impact factor: 3.633

3.  Increased Circulating Th17 but Decreased CD4+Foxp3+ Treg and CD19+CD1dhiCD5+ Breg Subsets in New-Onset Graves' Disease.

Authors:  Jing Qin; Jin Zhou; Chenling Fan; Na Zhao; Yongping Liu; Shuo Wang; Xuejiao Cui; Mingshi Huang; Haixia Guan; Yushu Li; Zhongyan Shan; Weiping Teng
Journal:  Biomed Res Int       Date:  2017-11-13       Impact factor: 3.411

Review 4.  Genetics, Epigenetics, Cellular Immunology, and Gut Microbiota: Emerging Links With Graves' Disease.

Authors:  Fangyu Zhou; Xin Wang; Lingjun Wang; Xin Sun; Guiqin Tan; Wenwen Wei; Guangbing Zheng; Xiaomin Ma; Dan Tian; Hongsong Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-04

5.  Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study.

Authors:  Tomonori Sekizaki; Hiraku Kameda; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Kiyohiko Takahashi; Arina Miyoshi; Norio Wada; Jun Takeuchi; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
Journal:  J Diabetes Investig       Date:  2021-06-16       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.